ADCT

ADC Therapeutics SA

1.51

USD

-0.16

-9.58%

Nov 10, 15:57 UTC -5

Closed

After-Market

1.51

0.00

+0.33%

ADC Therapeutics SA (ADCT) Earnings

ADCT Earnings Reports

Positive Surprise Ratio

ADCT beat 16 of 25 last estimates.

64%

Next Report

Today

Date of Next Report

Nov 10, 2026

Estimate for Q3 26 (Revenue/ EPS)

$19.07M

-$0.21

Implied change from Q2 26 (Revenue/ EPS)

-0.95%

+133.33%

Implied change from Q3 25 (Revenue/ EPS)

+16.06%

-30.00%

ADC Therapeutics SA earnings per share and revenue

On Aug 13, 2026, ADCT reported earnings of -0.09 USD per share (EPS) for Q2 26, beating the estimate of -0.21 USD, resulting in a 58.37% surprise. Revenue reached 19.25 million, compared to an expected 19.76 million, with a -2.61% difference. The market reacted with a -14.63% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.21 USD, with revenue projected to reach 19.07 million USD, implying an increase of 133.33% EPS, and decrease of -0.95% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were ADC Therapeutics SA's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, ADC Therapeutics SA reported EPS of -$0.09, beating estimates by 58.37%, and revenue of $19.25M, -2.61% below expectations.

How did the market react to ADC Therapeutics SA's Q2 2026 earnings?

The stock price moved down -14.63%, changed from $1.23 before the earnings release to $1.05 the day after.

When is ADC Therapeutics SA expected to report next?

The next earning report is scheduled for Nov 10, 2026.

What are the forecasts for ADC Therapeutics SA's next earnings report?

Based on -- analysts, ADC Therapeutics SA is expected to report EPS of -$0.21 and revenue of $19.07M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.